SG Americas Securities LLC Has $12.16 Million Stake in Sarepta Therapeutics, Inc. $SRPT

SG Americas Securities LLC raised its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 192.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 559,063 shares of the biotechnology company’s stock after buying an additional 367,692 shares during the quarter. SG Americas Securities LLC owned about 0.53% of Sarepta Therapeutics worth $12,165,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of SRPT. AQR Capital Management LLC boosted its stake in Sarepta Therapeutics by 454.6% during the 4th quarter. AQR Capital Management LLC now owns 7,796,535 shares of the biotechnology company’s stock worth $167,781,000 after acquiring an additional 6,390,860 shares during the last quarter. Vanguard Group Inc. increased its stake in Sarepta Therapeutics by 18.1% in the third quarter. Vanguard Group Inc. now owns 10,817,446 shares of the biotechnology company’s stock valued at $208,452,000 after purchasing an additional 1,657,267 shares in the last quarter. First Trust Advisors LP increased its stake in Sarepta Therapeutics by 209.1% in the third quarter. First Trust Advisors LP now owns 1,939,781 shares of the biotechnology company’s stock valued at $37,380,000 after purchasing an additional 1,312,220 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in Sarepta Therapeutics by 183.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,745,051 shares of the biotechnology company’s stock valued at $33,627,000 after purchasing an additional 1,129,610 shares in the last quarter. Finally, Erste Asset Management GmbH raised its holdings in Sarepta Therapeutics by 65.7% in the third quarter. Erste Asset Management GmbH now owns 2,685,945 shares of the biotechnology company’s stock worth $50,588,000 after purchasing an additional 1,064,530 shares during the period. 86.68% of the stock is owned by institutional investors.

Analysts Set New Price Targets

SRPT has been the topic of a number of recent analyst reports. Citigroup lifted their price target on shares of Sarepta Therapeutics from $9.00 to $13.00 and gave the stock a “sell” rating in a research report on Thursday, March 26th. Wells Fargo & Company lowered their price objective on shares of Sarepta Therapeutics from $45.00 to $38.00 and set an “overweight” rating for the company in a research report on Friday, February 27th. Weiss Ratings raised Sarepta Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, June 11th. Oppenheimer reiterated an “outperform” rating and set a $37.00 target price on shares of Sarepta Therapeutics in a report on Thursday, March 19th. Finally, Loop Capital set a $25.00 target price on Sarepta Therapeutics in a research note on Tuesday, March 3rd. Eight analysts have rated the stock with a Buy rating, ten have given a Hold rating and six have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $24.81.

Sarepta Therapeutics Stock Up 5.2%

Sarepta Therapeutics stock opened at $16.85 on Friday. The company has a 50 day moving average of $18.12 and a 200-day moving average of $19.46. The company has a quick ratio of 2.62, a current ratio of 4.63 and a debt-to-equity ratio of 0.56. Sarepta Therapeutics, Inc. has a twelve month low of $10.41 and a twelve month high of $25.32. The stock has a market capitalization of $1.78 billion, a PE ratio of -17.55, a price-to-earnings-growth ratio of 0.17 and a beta of 0.21.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $3.16 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $2.18. The business had revenue of $730.80 million for the quarter, compared to analyst estimates of $474.15 million. Sarepta Therapeutics had a negative net margin of 2.94% and a positive return on equity of 7.56%. The firm’s quarterly revenue was down 1.9% on a year-over-year basis. During the same period last year, the business posted ($3.42) earnings per share. On average, equities research analysts anticipate that Sarepta Therapeutics, Inc. will post 3.95 EPS for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.